New hope for advanced lung cancer: drug duo aims to shrink tumors

NCT ID NCT07027514

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 20 times

Summary

This early-stage study tests a new drug called tolododekin alfa combined with an immunotherapy for people with advanced non-small cell lung cancer. The goal is to see if the combination can shrink tumors and control the disease. About 60 participants will join, including those who have already tried standard treatments and those who are new to therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Barbara Ann Karmanos Cancer Hospital

    RECRUITING

    Detroit, Michigan, 48201, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Community Health Network

    RECRUITING

    Indianapolis, Indiana, 46256, United States

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • FirstHealth of the Carolinas

    RECRUITING

    Pinehurst, North Carolina, 28374, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Icahn School of Medicine at Mount Sinai

    RECRUITING

    New York, New York, 10029, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Roswell Park Comprehensive Cancer Center

    RECRUITING

    Buffalo, New York, 14263, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.